Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Obstructive Pulmonary Disease

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease

Clinical Trial

Last updated: 3/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Related Pipeline

Hypercholesterolemia

Triple Negative Breast Neoplasms

Generalized Anxiety Disorder

Metastatic Castration-resistant Prostate Cancer

Diabetes Mellitus, Type 2